DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Plain-language summary
This trial is testing Alectinib for patients with anaplastic large cell lymphoma (ALCL) at various stages of their disease. This is a Phase 2/3 trial that tests how well the treatment works and may compare it to standard care. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Must be well enough for treatment (adequate performance status)
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Alectinib (DRUG): Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily. Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.
Alectinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details